These initial successes support the general utility of the discovery process for pH-dependent mAbs, not just for immune-regulatory targets such as CTLA-4 and VISTA, but also for improving the on-target/off-tumor effects of targeting tumor-associated antigens on the cell surface of tumor cells. This evidence concerns the gene CTLA4 and neoplasm.